Search results
136 results found
Accelerating genomic medicineBlogA new NHS England (NHSE) strategy, Accelerating genomic medicine in the NHS, was released on 12th October, alongside the first NHS Genomics Healthcare Summit in London.
Biomarkers and cancer precision medicineBlogA set of consensus statements on the use of biomarkers in cancer research and treatment were released this month. We discuss what these mean.
Genomics, research, health and policy: new UK government directionsBlogNew policy releases from the UK Department of Health and Social Care review recent developments and set out plans
Examining whether viruses can combat antimicrobial resistanceBlogThe UK House of Commons Science and Technology Committee has announced a new inquiry that will explore the antimicrobial potential of bacteriophages (phages), a topic explored by the PHG Foundation in our 2021 policy briefing on phage therapy.
Making the most of genomics: supporting clinical research and careBlogThe UK House of Commons Science and Technology Committee has announced a new inquiry that will explore the antimicrobial potential of bacteriophages (phages), a topic explored by the PHG Foundation in our 2021 policy briefing on phage therapy.
Cancer, screening, and polygenic scoresBlogScreening is an important aspect of disease control and can support diagnosis and treatment of early stage disease.
CAR-T cell therapy for lupusBlogCAR-T cell therapy involves genetically engineering T cells, a type of immune cell, so that they respond to a prespecified molecular marker, or antigen.
Are data trusts trustworthy?BlogData is vital to health innovation but there remains a common feeling of mistrust in those who hold that data. Dr Elizabeth Redrup Hill considers why and what can be done to engender greater trust.
Fragmentomics – the future of cfDNA testing?BlogOutlining the work of Prof. Dennis Lo and his team on the emerging science of fragmentomics.
Synthetic health data, real regulatory challengeBlogSynthetic health data is a new form of data generation which demands new regulatory approaches to deliver the benefits to patient care we all would like to see, argues Dr Colin Mitchell